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Sperm vitality testing is a basic semen examination that has been described in the World Health Organization (WHO) Laboratory Manual for the Examination and Processing of Human Semen from its primary edition, 40 years ago. Several methods
can be used to test sperm vitality, such as the eosin-nigrosin (E-N) stain or the hypoosmotic swelling (HOS) test. In the 6th
(2021) edition of the WHO Laboratory Manual, sperm vitality assessment is mainly recommended if the total motility is less
than 40%. Hence, a motile spermatozoon is considered alive, however, in certain conditions an immotile spermatozoon can
also be alive. Therefore, the differentiation between asthenozoospermia (pathological decrease in sperm motility) and necrozoospermia (pathological decrease in sperm vitality) is important in directing further investigation and management of infertile patients. The causes leading to necrozoospermia are diverse and can either be local or general, testicular or extra-testicular. The andrological management of necrozoospermia depends on its etiology. However, there is no standardized treatment
available presently and practice varies among clinicians. In this study, we report the results of a global survey to understand
current practices regarding the physician order of sperm vitality tests as well as the management practices for necrozoospermia. Laboratory and clinical scenarios are presented to guide the reader in the management of necrozoospermia with the
overall objective of establishing a benchmark ranging from the diagnosis of necrozoospermia by sperm vitality testing to its
clinical management.
Keywords: Asthenozoospermia; Eosine Yellowish-(YS); Infertility; Nigrosin; Spermatozoa; Vitality
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION
Sperm vitality, assessed by eosin-nigrosin (E-N) stain,
refers to the integrity and permeability of the cell
membrane, while sperm viability, assessed by hypoosmotic swelling (HOS) test, refers to the percentage of
live spermatozoa in the semen. In laboratory practice,

however, the terms “vitality” and “viability” are commonly used interchangeably [1] as they both refer to
sperm membrane function and thereby whether or not
the male germ cell is dead or alive. The assessment of
human sperm vitality is an important parameter of
basic semen analysis [2-4]. This test is commonly conducted in andrology laboratories and assisted reproducwww.wjmh.org

229

https://doi.org/10.5534/wjmh.210149

tive technology (ART) clinics and the methodology is
described in the 5th (2010) edition of the World Health
Organization (WHO) Laboratory Manual for the Examination and Processing of Human Semen [5]. In this
5th edition, it is stated that sperm vitality testing is
possible on all semen samples but is mainly recommended if the progressive motility is lower than 40%.
The choice of a progressive motility threshold is surprising and confusing. Indeed, a spermatozoon, even a
non-progressive motile one, can be alive. Moreover, the
threshold of 40% corresponds to the reference threshold of total motility [3,5,6]. Both these arguments have
been addressed in the latest (6th) edition of the WHO
manual, available since July 2021. According to the 6th
edition, it is not necessary to assess vitality when at
least 40% of spermatozoa are motile [7]. Thus, in this
article, we will describe the sperm vitality test as necessary if total motility is below 40%.
Regarding the definition of necrozoospermia, the
WHO 5th edition states that the lower reference
threshold of sperm vitality is set at 58%. Normal sperm
vitality is applied to samples with ≥58% (5th centile;
95% confidence interval [CI], 55%–63%) alive spermatozoa [5]. Thus, necrozoospermia was defined as the

presence of less than 58% of alive spermatozoa in semen. The 6th edition of the WHO manual has removed
the standards and reference values, arguing that the
boundaries between sperm from infertile and fertile
men were not as clear [7].
Vitality should be examined in conjunction with
motility in the same sample. The purpose of assessing
both sperm vitality and motility is to clarify whether
immotile spermatozoa seen in ejaculates with low
sperm motility are dead or alive (Table 1). Vitality testing can also provide a counter-check on the motility
evaluation, since the percentage of dead cells should
not exceed (within sampling error) the percentage of
immotile spermatozoa [5]. The importance of a proper
diagnosis must be emphasized here as the management
of asthenozoospermia is different from that of necrozoospermia in many instances, which is why a clear
discrimination should be pursued.
The most commonly used method to assess sperm vitality is the combined E-N stain [7]. The prevalence of
its use at the College of American Pathologists (CAP)
certified clinics and laboratories across the United
States is 62.8% (359/572) (CAP Proficiency report, May
2021; Supplement File 1). The E-N test is automati-

Table 1. Summary of the clinical and laboratory aspects pertaining to necrozoospermia
Testing for necrozoospermia
Indication: if total sperm motility is less than 40%
Importance: in order to distinguish whether the immotile spermatozoa are dead (necrozoospermia) or are alive but with abnormal motility
(asthenozoospermia), as this will have clinical implications in terms of approach and management
Methods:
• Eosin-nigrosin staining: dead sperm heads are stained dark pink or red – all tested sperm are damaged and can no longer be used for ART
• HOS test: live sperm tails become swollen – sperm is not damaged and can be used for ART
Causes and risk factors of necrozoospermia
• Genital tract infections – the most common cause
• Testicular hyperthermia – local or systemic (such as fever)
• Varicocele
• Hyperthyroidism
• Spinal cord injury
• Polycystic kidney disease
• Antisperm antibodies
• Advanced male age
• Toxic substances – such as: tobacco, cannabis, pesticides
• Idiopathic
Note: Should always rule out false results due to lubricant use or contamination of semen sample with antiseptic solution, soap, or water
Management of necrozoospermia
• Avoiding and treating underlying risks and conditions
• Frequent ejaculation
• Absolute asthenozoospermia: consider the diagnosis of flagellar dyskinesia - perform HOS test or use enhancers of sperm motility and
select viable sperm for ICSI
• Absolute necrozoospermia: consider SDF testing if ejaculated live sperm are to be used in ICSI, testicular sperm extraction followed by ICSI
ART: assisted reproductive technology, HOS: hypoosmotic swelling, ICSI: intracytoplasmic sperm injection, SDF: sperm DNA fragmentation.
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cally conducted by the laboratory technologist within
the requirements of a basic semen analysis in cases of
asthenozoospermia (<40% total motility). For this test,
eosin is used as a vitality dye in the evaluation of the
integrity of the sperm membrane. An intact membrane
will not be penetrated by eosin, unlike compromised
membranes of dead sperm. One of the drawbacks of
the E-N test is that stained spermatozoa cannot be
used in subsequent procedures, namely in ART. Therefore, in such cases sperm viability should be tested in a
manner which is not detrimental to the spermatozoa to
be used in ART. The HOS test, for example, is compatible with fertilization procedures [1,8-11].
In the current review article, we describe the technical characteristics of sperm vitality tests and discuss
the etiology and management of necrozoospermia. We
also present laboratory and clinical scenarios on the
relevance, utilization, and significance of sperm vitality
testing. Additionally, we provide the results of a short
global survey on the current practice patterns of sperm
vitality testing among infertility specialists.

SPERM VITALITY ASSESSMENT
Sperm vitality assessment should be performed with
an abstinence period of 2 to 7 days [7]. The patient collects the specimen into a sterile container. The semen

A

B
50 L drop of
well-mixed
semen

50 L
E-N solution

sample should be stored at 37°C and the sperm vitality
test must be performed after liquefaction within 30
minutes to one hour after collection. This prevents the
deleterious effects of dehydration and temperature on
sperm vitality [7].

1. Eosin-nigrosin staining

The most commonly used method to assess sperm vitality is the combined E-N stain. In this method, eosin
is a supravital stain and nigrosin is a purple dye that
serves as a counterstain [7]. Here we describe the stepby-step protocol for performing the vitality test (Fig. 1)
along with the reagents, consumables, and equipment
required (Fig. 2).
The E-N stain is prepared by dissolving 0.67 g of eosin Y and 0.9 g of sodium chloride (NaCl) in 100 mL of
distilled water and this mixture is then placed on a hot
plate to undergo gentle heating. Then 10 g of nigrosin
is added to 100 mL of eosin Y solution. The suspension
is boiled, then allowed to cool to room temperature. It
is next filtered through a filter paper to remove coarse
and gelatinous precipitates. The E-N stain is stored in
a sealed dark-glass bottle.
To perform the vitality test, two frosted slides are labeled with patient’s name, medical record number, and
date. Fifty microliters of well-mixed semen are placed
into a Boerner slide well (or a test-tube) and equal

C
Pipette 10 L of
mixture onto slides

Make one
thin smear
and let dry

Once dried, add a
drop of non-aqueous
mounting medium on
the smear and place
a coverslip over it

Observe: 1,000x (oil)
Count 100 sperm on each slide twice
Count vital sperm (unstained)
Count non-vital sperm (stained)

Record results in replicate
Report average percentage of
vital sperm

Fig. 1. Schematics of the steps involved
in conducting the vitality test. (A)
Fifty microliters of well-mixed semen is
placed into a Boerner slide well. Equal
volume of E-N stain is added. The sample
is mixed well with a wooden stirrer, and
left to sit for 30 seconds. (B) Immediately
after that, ten microliters of the mixture
is placed on the labeled frosted slide and
a thin smear is made. Perform this step
in duplicate. Once the smear is air-dried,
a coverslip is placed on the mounting
media. (C) A drop of immersion oil is
placed on each of the mounted slides.
One hundred spermatozoa are observed under bright-field microscopy
with 1,000x magnification. This step
is performed twice on each slide. The
vital (unstained) and non-vital (stained)
sperm are counted. Results are recorded
in replicate and the average percentage
of vital sperm is reported.
www.wjmh.org
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Bright-field microscope

Mounting medium

Lint-free wipes

Differential counter

Immersion oil
(refractive index=1.52)

Lens cleaener solution

volume of E-N stain is added, and the sample is mixed
well with a wooden stirrer, then it is let to settle for 30
seconds (Fig. 1A).
The nigrosin stain provides a dark background that
makes it easier to distinguish faintly stained spermatozoa. Immediately two thin smears are made by pipetting 10 µL of the mixture and placing on each of the
labeled slide. After air-drying the smear, a coverslip is
placed on the non-aqueous mounting media (Fig. 1B). A
drop of immersion oil (refractive index=1.52) is placed
on the mounted slide, and spermatozoa are observed
with 100× objective and a 10× eye-piece at a total magnification of 1,000× under a bright-field microscopy
(Fig. 1C). White or faint pink sperm heads indicate
vital spermatozoa (Fig. 3A, 3B), while red or dark pink
heads indicate non-vital spermatozoa (Fig. 3C). If the
stain is limited only to a part of the neck region, and
the rest of the head area is unstained (Fig. 3B), this is
considered a “leaky neck membrane”, and it is not a
sign of cell death and total membrane disintegration.
These cells should be assessed as alive. Routine method
of counting at least 200 spermatozoa gives sufficiently
accurate results for the intended clinical purpose of
establishing whether the immotile spermatozoa seen in
the ejaculate with low sperm motility are alive or not
[12]. The percentage of vital sperm is reported.
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A

Fig. 2. Equipment, reagents, and consumables, required for components of
the eosin-nigrosin test.

Unstained sperm (alive)

B

Leaky sperm (alive)

C

Stained sperm (dead)

Fig. 3. Schematic representation of alive (A, B) and dead sperm (C)
after eosin-nigrosin staining.

2. Hypoosmotic swelling test

This test evaluates the functional integrity of the
sperm plasma membrane and also serves as a useful
indicator of fertility potential [8]. Functional integrity
can be demonstrated by allowing sperm to react in a
hypoosmotic medium. The membrane is semi-permeable
in live cells, therefore cells with intact membranes (live
cells) will swell in hypotonic solutions. The HOS test
has high reproducibility and accuracy and is closely
correlated to the in vitro fertilizing ability of spermato-

Ashok Agarwal, et al: Sperm Vitality and Necrozoospermia

A

B

c
a

d

e

f

g

b

Differential counter

Fig. 4. (A) Components of the hypoosmotic swelling test. (B) Semen
sample observation under a phase contrast microscope 40× objective and 10× eye piece, and sperm differentiation according to tail
swelling. (a) Non-swollen tail of a dead spermatozoon. (b–g) Different patterns of swollen tails of alive spermatozoa.

zoa [13,14].
For HOS testing, a hypoosmotic solution is prepared
by adding 0.735 g sodium citrate dehydrate and 1.351 g
D-fructose in 100 mL of distilled water. A well-mixed
0.1 mL aliquot of semen is mixed with 1 mL HOS solution (Fig. 4). The sample is mixed gently by continuous
pipette suction and release and incubated at 37oC for
30 minutes. Following incubation, 1 drop of the semen mixture is placed on a glass slide with a coverslip.
This test is performed as a duplicate. The percentage
of spermatozoa demonstrating tail swelling (Fig. 4A)
are counted under 40× phase contrast lens. A total assessment of 200 spermatozoa for tail swelling/coiling is
performed using a 2-channel differential cell counter.
The average percentage of live sperm showing tail
swelling is calculated. The normal threshold is ≥58%
(95% CI, 55%–63%) of spermatozoa with tail swelling
(Fig. 4B) according to the guidelines in the WHO 5th
edition manual [5].

3. Quality control and quality assurance
1) Quality control of the eosin-nigrosin stain
and hypoosmotic swelling reagents

For E-N staining, a monthly patient quality control

(QC) is required to check the quality of the stain. A QC
step is performed each time new reagents are prepared.
This must be performed before a new stain is used to
test further patient specimens [15]. The total motility
of the specimen should be assessed prior to the QC protocol. The specimen should be stained with both the old
lot of stain as well as the new lot. Both sets of slides
should be scored for sperm vitality. The percentage of
viable sperm should be greater than or equal to the
total motility of the specimen used. The comparison
of the 2 lots of reagents should be within 10% of each
other. If results are not within the acceptable range,
the staining must be repeated using another specimen
[15]. Similarly, when a new HOS reagent is prepared,
QC must be performed before they can be used to test
further semen samples. A positive control is prepared
using a normal semen sample and run monthly or
when a fresh reagent is prepared with a result of ≥58%
to verify that the HOS reagents meet the criteria and
can be used for patient testing. All results need to be
verified and recorded when the control is run.

2) Internal quality control

Both vitality and viability slides are scored by two
observers (RKS and SG) and the results are compared.
A Bland–Altman plot can be used to check the correlation of inter-technician sperm vitality results.

3) External quality control

Two control vitality slides are prepared by accreditation laboratories and are assessed every six months for
external QC. The designated technologist scores at least
200 spermatozoa and records results on the data sheet
as percent viable. Results should be within ±2 standard
deviation of mean for all laboratories as reported by
the accreditation agency. Corrective action must be
undertaken if the results are not within the specified
range. The technologist will have to be retrained in
the test and then instructed to re-score the proficiency
slides [15].

LABORATORY SCENARIOS
Some laboratory issues may be encountered during
the preparation and scoring of the smears for vitality.
Recommendations for troubleshooting are illustrated
in the following scenarios.

www.wjmh.org
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1. Case A
1) Scenario

A 28-year-old patient provides a semen sample for
laboratory evaluation. Upon examination, the sperm
parameters are (1) volume, 3.3 mL; (2) concentration,
37×106/mL; (3) total motility, 15%. How will you proceed?

2) Solution

Total motility is below 40%. Prepare the slides by
following the steps for E-N staining. The percentage of
vital and non-vital spermatozoa must be counted and
compared with motility. The vitality results must be
equal to or greater than the sperm total motility.

2. Case B
1) Scenario

A 30-year-old patient provides a semen sample for
laboratory evaluation. Upon examination, the parameters are (1) volume, 0.5 mL; (2) concentration, 5×106/
mL; (3) total motility, 10%. How will you proceed?

2) Solution

All three parameters are below the WHO reference
values [5]. Since the concentration is below 10×106/mL,
first centrifuge the sample at 3,000 g for 7 minutes.
Gently remove approximately 300 µL of the supernatant. After mixing the pellet thoroughly, perform the
E-N test as previously described. Note on the frosted
label “spun” indicating that it is a spun smear. The
percentage of vital and non-vital sperm must be counted, and vitality compared with motility. The vitality
results must be equal to or greater than the sperm total motility. Vitality test can indeed provide a check on
the motility evaluation, since the percentage of dead
cells should not exceed (within sampling error) the percentage of immotile spermatozoa [5]. If the evaluation
of sperm vitality and motility are discordant (presence
of less live sperm than motile sperm), the evaluation of
these two parameters should be redone.

3. Case C
1) Scenario

A 35-year-old patient provides a semen sample for
laboratory evaluation. Upon examination, the param-
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eters are (1) volume, 2.5 mL; (2) concentration, 20×106/
mL; (3) progressive motility, 30%. The sample is examined for vitality and a majority of the spermatozoa
show sperm heads that are neither completely white
nor completely stained pink. How will you proceed?

2) Solution

This is an example of “leaky” sperm. The neck region
is very fragile and is the first to show signs of damage. The membrane breakdown may be very minimal
at the initial stages and so there is a minute portion
of stain that can enter the base of the head and neck
region. Therefore, only a limited amount of pink stain
is observed, and the rest of the sperm head is white
(Fig. 3B). Spermatozoa with an appearance as described above following staining should be scored as
vital. Gradually the damage may spread to the rest
of the sperm head. This allows the stain to penetrate
the sperm head and the extent of the pink stain may
be more than at the base but still some portion of the
head may be unstained and appear white. Spermatozoa
that are stained pink should be reported as non-vital
(Fig. 3C).

ETIOLOGIES OF
NECROZOOSPERMIA
Proper patient history is essential to eliminate false
results of necrozoospermia. For example, the addition of lubricants during masturbation or inadvertent
spillage of antiseptic solution, soap or water into the
semen collection sample may be responsible for false
results. In such cases, another specimen should be collected following detailed instructions and submitted
for vitality assessment. Necrozoospermia is reported to
have a prevalence of 0.2% to 0.4% in infertile males [1618]. Causes of necrozoospermia could either be local or
general, testicular or extra-testicular, and some of them
can be associated in the same patient (Table 1) [16,19-28].
Infections may account for nearly half of the causes
of necrozoospermia [16]. The alteration of sperm vitality can be explained by several mechanisms: direct
damage to spermatozoa by infectious organisms, effects
of inflammatory mediators and/or possible long-term
alteration of the genital tract environment [23]. With
regard to the epididymal environment, the first to describe epididymal necrozoospermia was Wilton in 1988
[29]. The epididymis could indeed be dysfunctional and
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lead to sperm abnormalities such as asthenozoospermia
and necrozoospermia. The mechanisms of action involved could be multiple, including exposure of epididymal spermatozoa to oxidative stress. This is why some
necrozoospermic cases, previously considered as due to
“epididymal” causes [29], are now better explained by
the possible action of seminal oxidative stress [30].
Some necrozoospermia can also be linked to an impairment of spermatogenesis. Testicular heat stress is
a well-known mechanism for altering spermatogenesis
[31], as heat is indeed the basis of thermal male infertility [32,33]. Hence, local or general hyperthermia
(prolonged heat exposure, fever, hyperthyroidism, obesity, varicocele, etc.) can lead to necrozoospermia. For
instance, Abalovich et al [24] described a large cohort
of patients with hyperthyroidism presenting with
necrozoospermia. These abnormalities were corrected
in most of the cases, with the establishment of normal
thyroid function. The mechanisms of action could be
hormonal with a decrease in testosterone, or thermodysregulation as related to the increase in body heat
[24]. For patients with varicocele, the pathophysiological mechanisms of necrozoospermia involve an increase
in local temperature as well as the simultaneous formation of reactive oxygen species (ROS) [34]. More
recently, with the appearance of the Coronavirus Disease-2019 (COVID-19) pandemic, it was described that
fever, even without the presence of the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in
the semen, could induce an alteration in spermatogenesis and a decrease in sperm vitality [35]. It is therefore
important to consider medical and reproductive history throughout the assessment, along with a thorough
physical examination in patients with necrozoospermia
in view of the wide spectrum of possible etiologies.
Necrozoospermia can also be observed following longterm exposure to toxic substances such as tobacco, cannabis and pesticides, amongst others [20-22,25,36-39].
A direct toxic effect of cannabis can be noted via the
presence of cannabinoid receptors in testicular tissue
(Sertoli and Leydig cells) and this would lead to the
inhibition of mitochondrial respiration and the loss of
energy in sperm, followed by death [25,38]. Necrozoospermia is also commonly reported in patients with
spinal cord injury [27,40]. For these patients, other
causes of necrozoospermia could include the thermal
dysregulation induced by a prolonged sitting stance
that promotes temperature increase in the male genital

area. These patients are also more at risk of urogenital
infections.
Certain cytotoxic antibodies can also cause necrozoospermia. In a case report of a patient who underwent
vasectomy reversal, the presence of necrozoospermia
was associated with a positive test for antisperm antibodies [28]. Antisperm antibodies, produced locally
in the seminal tract following the disruption of the
epithelial tight-junction barrier, affect the overall motility of the samples involved and could be responsible
for necrozoospermia. Furthermore, necrozoospermia
has been found to be associated with polycystic kidney
disease [19]. In these patients, cystic obstructions/dilatations of the seminal vesicles and ejaculatory duct (due
to seminal vesicle atony) have been described as responsible for sperm stasis in the genital tract, followed
by sperm death [41]. Advanced male age may also be
accompanied by necrozoospermia. The mechanisms
remain unknown at this time but may involve an alteration in accessory gland secretions [42-44]. However,
after a complete andrological evaluation, some patients
with necrozoospermia remain idiopathic.

MANAGEMENT OF
NECROZOOSPERMIA
The first line of management in necrozoospermia is
avoiding any etiological contributory factors mentioned
previously (exposure to heat, modification of lifestyle,
treatment of urogenital infections, correction of hyperthyroidism, etc.). In addition, if vitality is affected
by infrequent ejaculations and prolonged epididymal
storage, the parameters of sperm vitality could be improved by repeated ejaculations (60 minutes, 12 hours
or 24 hours after the first ejaculate) [29,45,46].
Here we describe two conditions when (1) necrozoospermia is not absolute but asthenozoospermia is, and
(2) when necrozoospermia is absolute.

1. Management of necrozoospermia with
absolute asthenozoospermia

When no motile spermatozoa are observed, sperm
vitality should be tested to differentiate asthenozoospermia from necrozoospermia. The presence of a large
proportion of live but immotile spermatozoa may indeed be indicative of structural defects in the flagellum [7,47,48]. There is no definition in the latest edition
of the WHO manual of this “large proportion of imwww.wjmh.org
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motile living spermatozoa”, but it is considered that “if
more than 25%–30% of all spermatozoa are alive and
immotile, a genetic ciliary problem may be the cause”
[7]. If flagellar dyskinesia is suspected, other clinical or
sperm elements may help the diagnosis (Table 1). For
example, the observation of short, bent or coiled flagella may be suggestive of such flagellar/ciliary problems
[49].
In practice, if the spermatozoon is immotile and ART
is being considered for the couple, it is necessary to test
sperm vitality. In order to select a viable spermatozoon
for intracytoplasmic sperm injection (ICSI), the HOS
test is very useful in cases where no motile spermatozoa are present through microscopic examination [11].
At this instance, a modification of the main approach
in HOS testing should be adapted for subsequent use
for fertilization through ICSI, where the embryologist
should aspirate the selected spermatozoon head first
with the injecting needle and immerse the flagellum
in a hypoosmotic solution for less than 5 minutes [7].
As soon as the tail swelling is visualized, the spermatozoon is considered as viable and is removed from the
hypo-osmotic solution and rinsed in culture medium
allowing osmotic equilibrium. Immotile testicular spermatozoa when selected with HOS and used for ICSI
result in higher fertilization and pregnancy rates than
immotile sperm selected without being subjected to
HOS test [13,14]. HOS test could also be useful in cases
of previous ICSI failure due to oocyte fertilization failure [50]. The only situation where the HOS test is not
as useful would be in cases of cryopreserved semen
samples [51,52]. This might be related to the loss of integrity of the sperm membrane after cryopreservation,
which can lead to spontaneous swelling of the flagella
[53].
Several other approaches for selection of viable spermatozoa for ICSI have been presented [54]. The mechanical technique of “touching” the flagellum, known
as the sperm tail flexibility test (STFT), consists of
evaluating the flexibility or rigidity of the flagellum
by touching it with the ICSI pipette [55]. A dead spermatozoon would have a rigid flagellum. This technique
is subjective and difficult to control [53,54]. The laser
technique, known as the laser assisted immotile sperm
selection (LAISS), consists of performing a laser shot
of 129 microjoule for approximately 1.2 milliseconds
very close to the flagellum, using a non-contact diode
laser system [56]. The living spermatozoon then coils its
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flagellum. Like the HOS test, STFT and LAISS could
give false positives for frozen sperm as the flagellum
could spontaneously curl after freezing-thawing [53,54].
These two techniques, STFT and LAISS, have not been
described in recent years, probably because their costs
in terms of learning time (STFT) or in terms of equipment (LAISS) might limit their routine use in ART
laboratories [53,54,57].
Therefore, there are several techniques to test the
vitality of immobile spermatozoa. Most studies have
focused on activating substances such as pentoxifylline
(PTX) or theophylline describing their role in activating flagellar movement of immotile spermatozoa (for a
review see [53,54,57]). PTX is a 3′ 5′ nucleotidase phosphodiesterase inhibitor that improves sperm motility
by increasing intracellular cyclic adenosine monophosphate [58]. It has been studied in infertile patients since
the late 1980s [59]. Theophylline, which belongs to the
same family, has been studied less frequently since its
first clinical trial in 2011 [60]. Since then, several studies have shown the effectiveness of these substances
in inducing sperm motility in immotile but alive spermatozoa (for a review see [54,57]). Their safety has
been demonstrated in several studies (for a review see
[53,54,57]). However, given their potential toxicity, it is
necessary to rinse the spermatozoon before injecting it
into the oocyte [53,54,57].

2. Management of absolute necrozoospermia

If absolute necrozoospermia in the ejaculate is confirmed, then testicular sperm extraction should be considered (Table 1), since it allows the extraction of live
spermatozoa [61,62].
Necrozoospermia has been shown to be correlated
with sperm DNA fragmentation (SDF). Samplaski et al
[63] reported a strong direct correlation between sperm
vitality and normal DNA integrity (r=0.83, p<0.001).
Moreover, authors observed that SDF measured by
spermatozoa chromatin structure assay (SCSA) was
≤30% (normal) when sperm vitality was ≥75% in 95%
of samples. Similarly, SDF was ≥30% (high) when vitality was ≤50%. Two other studies showed the same
correlations between necrozoospermia and DNA fragmentation tested by the terminal deoxynucleotidyl
transferase-mediated deoxyuridine triphosphate nickend labeling (TUNEL) assay. SDF was significantly
higher in sperm with necrozoospermia [64,65]. Derbel
et al [66] found the same results using the sperm chro-
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matin dispersion test in leukocytospermia. Some of the
authors report a continuum between DNA damage
and sperm death. The loss of viability would be part
of a progressive oxidative process that starts with the
excessive generation of ROS, leads to the peroxidation
of membrane lipids and DNA damage, and ends in
DNA fragmentation and ultimately death [67]. Thus,
the question that must now be asked is the following:
even if some immobile spermatozoa are alive, can we
be confident of their nuclear integrity? The answer to
this question is probably a no. Testing for SDF could
then be useful in deciding whether to use live ejaculated sperm in ICSI or to use testicular sperm extraction. Nevertheless, interest in using antioxidants to reduce potential SDF in these patients with almost total
necrozoospermia is open for discussion. Antioxidants
may indeed have a beneficial effect on reducing SDF
[18,68,69].

CLINICAL SCENARIOS

2. Case B
1) Scenario

A patient presents for semen analysis and has the
following results: (1) semen volume, 3.5 mL; (2) sperm
concentration, 35×106/mL; (3) sperm motility, 0%; (4) vitality, 0%. How will you manage this patient?

2) Solution

First, rule out spermicidal lubricant use or improper
collection (with spillage of antiseptic solution, soap or
water into the semen collection container). Repeat semen analysis. If there is no pathological cause, ICSI using testicular sperm improves the chance of conception,
otherwise other alternatives should also be considered
(e.g., use of donor sperm).

3. Case C
1) Scenario

1. Case A

A patient presents for semen analysis. Upon analysis the following parameters are reported: (1) semen
volume, 4.5 mL; (2) concentration, 70×106/mL; (3) total
sperm motility, 0%. His spouse had an early spontaneous miscarriage a few months ago. No cause for necrozoospermia was found on questioning or clinical examination. How will you manage this patient?

1) Scenario

2) Management

There are several clinical and diagnostic conditions
or findings which indicate the need to perform the E-N
or HOS test to rule out necrozoospermia or asthenozoospermia.

A couple is undergoing ICSI procedure. On the day of
the procedure, a fresh sperm sample is examined, and
the embryologist identifies 6 spermatozoa, but none of
them display any motility. How should they proceed?

2) Solution

Since the spermatozoa are going to be used for ICSI,
assessing sperm viability is very important and hence,
E-N stain cannot be used. The solution is to use HOS
test, STFT, LAISS, PTX, or theophylline. If the sperm
is assessed as viable, it can be rinsed in sperm wash
medium and subsequently be used for oocyte injection. If the spermatozoon is not considered as viable,
the procedure is repeated until a viable sperm can be
retrieved. If absolute necrozoospermia is found (0% vitality), testicular sperm should be retrieved by surgical
sperm extraction.

Since the patient has a history of confirmed natural
fertility and no motility, performing a viability test is
recommended. Testing for SDF will help in the decision between using testicular and ejaculated sperm.
Antioxidants can be proposed as supplements to reduce
SDF if it is present.

ONLINE SURVEY
We have thus far described the principles of the
sperm vitality test, the causes of necrozoospermia and
discussed appropriate patient management. We now
present the results of a worldwide survey of andrologists/urologists that was conducted to evaluate practice
patterns in the management of necrozoospermia.

1. Methodology

The American Center for Reproductive Medicine
(ACRM) designed and conducted an online survey to
www.wjmh.org
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investigate the importance, use and clinical implication
of sperm vitality testing in male infertile patients. No
ethical approval was required for this study. Researchers and clinicians from ACRM drafted the questions
(AA, RKS, RF, SG, NP), which were subsequently revised by a pool of experienced andrologists, urologists,
and attending physicians with expertise in male infertility selected from all over the world. English was the
primary language of the survey and questions were
carefully revised to make them understandable for
non-native English speakers.
The survey consisted of 15 questions, in 2 different

sections: the first section (6 questions) aimed to collect
the demographic data of the participants, while the
questions in the second section targeted the clinical
practice pattern of sperm vitality testing (Supplement
File 2). We used SelectSurvey (https://www.classapps.
com/product_ssv5.aspx; ClassApps Inc., Kansas City,
MO, USA), a tool approved by the Information Technology Department, Cleveland Clinic, to securely populate the survey. A total of 106 international experts
in male infertility received the survey link by email
on June 19, 2021, and they were asked to complete the
survey by June 28, 2021. SelectSurvey automatically

Fig. 5. Geographic map illustrating the distribution of participants.

A

B
25 34 years
(n=3; 4.6%)

<2 years
(n=1; 1.5%)

65+ years
(n=7; 10.8%)

2 5 years
(n=3; 4.6%)

5 10 years
(n=11; 16.9%)

55 64 years
(n=10; 15.4%)

35 44 years
(n=23; 35.4%)

45 54 years
(n=22; 33.8%)

>10 years
(n=50; 76.9%)

Fig. 6. Pie charts reporting (A) the age of
participants and (B) their years of clinical
practice.
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generated a comma-separated values (CSV) file with
the results, which were analyzed using the MedCalc
Software (version 20.009; MedCalc Software, Ostend,
Belgium). Incomplete responses were excluded. Results
are reported as number of participants and percentage
calculated for each category. When more than one option was available, results were expressed in percentage based on the total number of participants.

setting was mostly identified as academic hospital/clinic (n=46, 70.8%) or private practice/clinic (n=22, 33.8%).
The majority of participants recommended sperm
vitality testing in their clinical practice (n=45, 69.2%).
The test is reported to be conducted on a weekly frequency (n=21, 46.7%), but the majority of practitioners
prescribe it less than 10 times a month (n=28, 62.2%).
More than half of them prescribe the test if the sperm
total motility is <25% (n=26, 57.8%), while only one
third of the participants conduct sperm vitality testing automatically when sperm motility is <40% (n=15,
33.3%) (Fig. 7).
The E-N test is reportedly the most commonly used
stain to test sperm vitality (n=35, 77.8%) and 73.0% of
the participants responded to order a test for SDF in
case of abnormal vitality (n=33, 73.3%) (Fig. 8A). Few
andrologists look for signs of infection or markers of
oxidative stress (n=21, 46.7% respectively) (Fig. 8A).
Concerning management, patients with necrozoospermia (0% sperm vitality) are mainly offered surgical
sperm retrieval followed by ICSI (n=41, 91.1%) (Fig. 8B).
Few andrologists recommended frequent ejaculation
(n=22, 48.9%) (Fig. 8B).
This survey highlighted that the WHO guidelines
(test vitality if total motility is <40%) are not necessarily applied in clinical practice. Few andrologists look for
signs of infection in the presence of necrozoospermia,
even though this is a frequent cause of reduced sperm
vitality. Regarding management, repetitive ejaculation
is a non-invasive option in comparison with surgical
sperm extraction. However, it seems to be given much
less consideration by the andrologists.

2. Survey results

The survey was completed by 65 out of 106 experts
(response rate: 61.3%). The participants originated from
31 countries (Fig. 5, Supplement File 3). Most participants’ ages were between 35 and 54 years old (n=45,
69.2%) (Fig. 6A), with >10 years of experience in clinical
practice (n=50, 76.9%) (Fig. 6B). Their primary practice

<50% sperm motility
(n=4; 8.9%)

<40% sperm
motility
(n=15; 33.3%)

<25% sperm
motility
(n=26; 57.8%)

Fig. 7. Pie chart reporting the use of sperm vitality in the andrology
laboratory.
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22

Other
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45 ation of patients with abnormal sperm

vitality. (B) Clinical options for management of necrozoospermic patients. ICSI:
intracytoplasmic sperm injection.
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CONCLUSIONS
Sperm vitality staining is a useful test that should
be performed when a semen sample shows reduced motility. It helps identify samples with necrozoospermia,
and thus points to a number of potentially correctable
clinical conditions that may contribute to impaired fertility. When all spermatozoa are immotile, then testing
to distinguish between “live-immotile” versus “dead-immotile” spermatozoa is critical in determining whether
ejaculated or testicular spermatozoa should be used
for the ICSI procedure. Furthermore, necrozoospermia
positively correlates with increased sperm DNA damage. Hence, SDF testing could be useful in patients
with low numbers of alive spermatozoa. Our global
survey reveals considerable diversity in approaches to
vitality testing, and a relatively limited approach to
the management of necrozoospermia, thus highlighting
the need for guidelines on this relevant topic.
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